Day: May 20, 2024

Form 8.5 (EPT/RI) – Alpha Financial Markets Consulting Plc **amendment**

Written by Customer Service on . Posted in Public Companies.

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)        Name of exempt principal trader: Investec Bank plc (b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Alpha Financial Markets Consulting plc (c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Alpha Financial Markets Consulting plc (d)        Date dealing undertaken: 17th May 2024 (e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If...

Continue reading

Hepsor U34 SIA, Hepsor AS group company, signed construction agreement for the construction of StokOfiss 34 project in Riga

Written by Customer Service on . Posted in Public Companies.

Hepsor U34 SIA, a subsidiary of Hepsor AS Group, and construction company Mitt&Perlebach signed a contract on May 17, 2024, for the construction of a development project called StokOfiss 34 in Riga at Ulbrokas 34. The construction contract is approximately 9.6 million euros, plus value-added tax. The development will consist of a commercial building with office, commercial, and warehouse space totaling approximately 8,740 square meters. Completion is planned for the third quarter of 2025. StokOfiss U34 is designed with Hepsor’s green mindset in mind, and the building has been issued an energy class A and BREEAM sustainability certificate at the “Very good” level. “StokOfiss U34 brings high-quality and modern business space to the Riga market, allowing clients to consolidate office, commercial, and warehouse...

Continue reading

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Written by Customer Service on . Posted in Public Companies.

ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the pricing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are expected to be approximately $1.7 million before deducting placement agent fees and estimated offering expenses. The offering is expected to close on May 22, 2024, subject to customary closing conditions. Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.